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ABSTRACT 48 
Background: Hundreds of genetic variants are thought to contribute to variation in asthma risk by 49 
modulating gene expression. Methods that increase the power of genome wide association studies 50 
(GWAS) to identify risk-associated variants are needed. 51 
Objective: To develop a method that aggregates the evidence for association with disease risk across 52 
expression quantitative trait loci (eQTLs) of a gene and use this approach to identify asthma risk genes. 53 
Methods: We developed a gene-based test and software package called EUGENE that (1) is applicable 54 
to GWAS summary statistics; (2) considers both cis- and trans-eQTLs; (3) incorporates eQTLs 55 
identified in different tissues; and (4) uses simulations to account for multiple testing. We applied this 56 
approach to two published asthma GWAS (combined N=46,044) and used mouse studies to provide 57 
initial functional insights into two genes with novel genetic associations. 58 
Results: We tested the association between asthma and 17,190 genes which were found to have cis-59 
and/or trans-eQTLs across 16 published eQTL studies. At an empirical false discovery rate of 5%, 48 60 
genes were associated with asthma risk. Of these, for 37 the association was driven by eQTLs located 61 
in established risk loci for allergic disease, including six genes not previously implicated in disease 62 
aetiology (eg. LIMS1, TINF2 and SAFB). The remaining 11 significant genes represent potential novel 63 
genetic associations with asthma. The association with four of these replicated in an independent 64 
GWAS: B4GALT3, USMG5, P2RY13 and P2RY14, which are genes involved in nucleotide synthesis or 65 
nucleotide-dependent cell activation. In mouse studies, P2ry13 and P2ry14 – purinergic receptors 66 
activated by ADP and UDP-sugars, respectively – were up-regulated after allergen challenge, notably 67 
in airway epithelial cells, eosinophils and neutrophils. Intranasal exposure with the receptor agonists 68 
induced the release of IL-33 and subsequent eosinophil infiltration into the lungs. 69 
Conclusion: We identified novel associations between asthma and eQTLs for four genes related to 70 
nucleotide synthesis/signaling, and demonstrate the power of gene-based analyses of GWAS. 71 
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KEY MESSAGES 72 
• In humans, asthma risk is associated with genetically-determined expression of four genes 73 
related to nucleotide synthesis (B4GALT3, USMG5) and nucleotide-dependent cell activation 74 
(P2RY13 and P2RY14). 75 
• In mice, intranasal exposure with selective agonists for P2ry13 (ADP) or P2ry14 (UDP-76 
glucose) induced the release of IL-33 and eosinophil infiltration into the lungs, in the absence of 77 
allergen stimulation. 78 
 79 
CAPSULE SUMMARY 80 
Using a new method for gene-based analysis of GWAS results, we identified a genetic association 81 
between asthma risk and eQTLs for B4GALT3 and USMG5, which are involved in the production of 82 
UDP-galactose and ATP respectively, and P2RY13 and P2RY14, two G protein-coupled receptors 83 
activated respectively by ADP and UDP-sugars. Functional studies in the mouse show that activation of 84 
P2ry13 or P2ry14 induces the release of IL-33 and eosinophil infiltration into the lungs, in the absence 85 
of allergen stimulation. Functional studies that characterize in depth the contribution of these four 86 
genes to asthma pathophysiology are warranted. 87 
 88 
KEY WORDS 89 
Inflammation, eQTL, transcriptome, predisposition, obesity, EUGENE, VEGAS, PrediXcan, TWAS, 90 
ZNF707, AOAH, CLK3, UDP-glucose 91 
 92 
ABBREVIATIONS 93 
AECs: airway epithelial cells. 94 
ADP: adenosine 5-diphosphate.  95 
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Alt: Alternaria allergen. 96 
ATP: adenosine 5-triphosphate. 97 
BALF: bronchoalveolar lavage fluid. 98 
CRE: cockroach allergen. 99 
DC: dendritic cells. 100 
eQTL: expression quantitative trait locus.  101 
FDR: false discovery rate. 102 
GWAS: Genome Wide Association Study. 103 
HDM: house dust mite. 104 
IL: interleukin. 105 
LD: linkage disequilibrium. 106 
SNP: single nucleotide polymorphism. 107 
UDP: uridine-diphosphoglucose (UDP-glucose)  108 
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INTRODUCTION 109 
Asthma is a highly polygenic disease, with potentially hundreds or thousands of risk variants with 110 
small effects contributing to variation in disease risk 1. A small number of risk-associated variants has 111 
been identified through genome-wide association studies (GWAS), but the majority remain to be 112 
mapped. Identifying risk-associated variants is important because these could point to genes that were 113 
not previously suspected to be involved in disease pathophysiology (eg. 2, 3) or that could represent 114 
drug targets with greater probability of clinical success 4, 5.  115 
 116 
Several approaches have been proposed to increase the power of GWAS to identify variants with a 117 
modest but reproducible association with disease risk. These include larger sample sizes, the analysis of 118 
more refined phenotypes 6, 7, multivariate association analysis of related phenotypes 8, gene-based 119 
association analyses 9, 10, and association analyses restricted to functional variants, such as those that 120 
regulate gene expression levels 11. The aim of this study was to develop a method that combined the 121 
two latter approaches and apply it to results from a published asthma GWAS to help identify new genes 122 
whose expression was  associated with genotype and related to disease risk. 123 
 124 
Specifically, we hypothesized that if the expression of a gene is causally related to asthma, and gene 125 
expression is regulated by multiple independent expression quantitative trait loci (eQTLs) , then a 126 
gene-based approach that captures the aggregate signals from these eQTLs would be expected to 127 
improve power over the alternative approach of testing each variant individually. Recently, Gamazon et 128 
al. 12 described a gene-based association method based on the same concept, called PrediXcan. Briefly, 129 
this approach includes three steps: first, for a given gene, eQTLs are identified from transcriptome data 130 
sets. Second, a model that can be used to predict gene expression levels based on the aggregate effect 131 
of those eQTLs is trained on a reference transcriptome data set. And third, this model is used to infer 132 
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expression levels for a target GWAS data set that includes individuals genotyped for those eQTLs but 133 
for whom actual gene expression levels might not be available. The genetically-inferred gene 134 
expression levels can then tested for association with the phenotype of interest (eg. asthma).  135 
 136 
As highlighted by Gamazon et al. 12, PrediXcan has several advantages over other gene-based tests, 137 
such as VEGAS 9. However, in our view, it has one major limitation: unlike VEGAS, it is not 138 
applicable to GWAS summary statistics, which are typically more readily available, and therefore can 139 
be applied to a larger sample size than available GWAS data sets with individual-level genetic data. 140 
The TWAS approach developed by Gusev et al. 13 addresses this caveat, but in its current release is 141 
applicable only to a relatively small number of genes (4,284 from two blood eQTL studies), cis- but not 142 
trans-acting eQTLs (eg. those located >1 Mb from the target gene), and to a single reference 143 
transcriptome dataset at a time.  144 
 145 
In this study, we developed a gene-based association approach, called EUGENE, that combines the 146 
biological focus of PrediXcan and TWAS, and the versatility of VEGAS. Our approach also considers 147 
eQTL evidence across different tissues and estimates empirical false discovery rates (FDR), while 148 
accounting for the LD between variants. We applied this new approach to a published asthma GWAS 14 149 
to try to identify novel genes whose genetic component of gene expression is associated with asthma 150 
risk. Finally, we investigated whether results from mouse models of experimental acute allergic asthma 151 
are consistent with a contribution of two selected genes to disease pathophysiology.  152 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
METHODS 153 
 154 
EUGENE approach 155 
The proposed gene-based approach is described in detail in the Online Repository. Briefly, for a given 156 
gene, our approach includes four steps. First, we identify a set of variants that influence gene 157 
expression in any cell type or tissue relevant to the disease or trait of interest, based on results from 158 
published eQTL studies. Including eQTLs identified in tissues not thought to be relevant for the disease 159 
of interest might improve power, but this is something we did not consider in our study. We include in 160 
this list eQTLs located in cis (< 1 Mb from the target gene) or trans (> 1 Mb away or in a different 161 
chromosome). This list is then reduced to a sub-set of eQTLs with linkage disequilibrium (LD) r2<0.1; 162 
we refer to these as “independent eQTLs” for a given gene. Second, we extract association results for 163 
these independent eQTLs from a disease or trait GWAS of interest and then calculate a gene-based 164 
statistic Q, as the sum of the 1-df chi-squares for the individual eQTLs. This represents the aggregate 165 
evidence for association in that GWAS across the independent eQTLs of that gene. Third, we perform 166 
simulations using individual-level genetic data to estimate the statistical significance of Q, while 167 
accounting for the residual LD between eQTLs. Fourth, false-discovery rate (FDR) thresholds are also 168 
estimated empirically to account for multiple testing. Simulations show that the type-I error rate of 169 
EUGENE is close to the nominal expectation (Table E1 in the Online Repository). The software and 170 
input files required to run EUGENE are freely available at https://genepi.qimr.edu.au/staff/manuelF. 171 
  172 
Application of EUGENE to published GWAS of asthma 173 
We applied EUGENE to a published asthma GWAS 14 to illustrate the utility of the proposed approach. 174 
This GWAS included 6,685 individuals with both asthma and hayfever and 14,091 asthma- and 175 
hayfever-free controls, all of European descent, tested for association with 4.9 million SNPs with a 176 
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minor allele frequency >1%. In the original analysis of individual SNPs, eleven independent variants 177 
were found to be associated with disease risk at a genome-wide significance level of P<3x10-8. We 178 
used EUGENE to identify genes with an association with disease risk in the Ferreira et al. study 14 at an 179 
empirical FDR of 0.05 (corresponding to a P-value threshold of 1.9x10-4). At this FDR level, 5% of 180 
genes called significant (ie. with a P<1.9x10-4) are expected to be false-positive associations. To 181 
confirm putative novel associations, we then applied EUGENE to an independent asthma GWAS, the 182 
GABRIEL study15, for which summary statistics are publicly available. After excluding overlapping 183 
samples (the Busselton study), results from the GABRIEL study were based on 9,967 asthmatics and 184 
15,301 controls. 185 
 186 
Predicted direction of effect of gene expression on asthma risk  187 
EUGENE can be used to identify a set of genes whose expression is determined by eQTLs, and for 188 
which the eQTLs are collectively associated with disease risk. However, unlike PrediXcan12 or 189 
TWAS13, EUGENE does not directly provide the predicted direction of effect of gene expression on 190 
disease risk. To understand whether a genetically determined increase in gene expression levels was 191 
predicted to increase or decrease disease risk, we compared the direction of effect of each eQTL on 192 
gene expression reported on the transcriptome GWAS with the effect on asthma risk reported in the 193 
Ferreira et al. 14 asthma GWAS. Based on this information, for each eQTL we report whether the allele 194 
associated with increased gene expression is associated with an increased or decreased asthma risk.  195 
 196 
Functional studies in the mouse 197 
We selected two putative novel asthma risk genes for preliminary functional studies in the mouse: 198 
P2RY13 and P2RY14. The criteria used to select these genes for functional follow-up were as follows: 199 
(1) significant gene-based association with asthma in the discovery GWAS at an empirical FDR of 5%; 200 
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(2) the eQTLs that contribute to the significant gene-based association were not in LD (r2<0.1) with 201 
established asthma risk variants (those with a P<5x10-8 in published GWAS of asthma, hayfever, 202 
eczema and/or allergies); and (3) the gene-based association replicated (P<0.05) in an independent 203 
GWAS. Four genes satisfied all three criteria: P2RY13, P2RY14, USMG5 and B4GALT3. We prioritized 204 
the former two for follow-up because functional experiments were feasible with available 205 
tools/reagents (both are cell-surface receptors). We performed two sets of experiments, which are 206 
described in detail in the Online Repository and were performed in accordance with the Animal Care 207 
and Ethics Committees of the University of Queensland (Brisbane, Australia).  208 
First, we used an established mouse model of acute allergic asthma 16 to identify the cell types 209 
in the lung that express P2ry13 and P2ry14 in the context of allergen-induced airway inflammation. 210 
Two groups of wild-type C57Bl/6 mice were anesthetized and sensitized intranasally (i.n.) with either 211 
saline solution (group 1) or 100 µg of HDM extract on day 0. Subsequently, mice were challenged with 212 
either saline (group 1) or 5 µg of HDM (group 2) at day 14, 15, 16 and 17 and sacrificed 3 hours later. 213 
Total RNA was isolated from the left lung and quantitative real-time PCR performed to measure overall 214 
gene expression. To identify individual cell types in the lung expressing P2ry13 and P2ry14, 215 
bronchoalveolar lavage fluid (BALF) was collected and cells stained with anti-P2ry13 or anti-216 
P2ry14antibodies. Cells were then stained with cell-type specific fluorescently labeled antibodies and 217 
enumerated using a BD LSR Fortessa cytometer. To assess expression in airway epithelial cells, 218 
paraffin-embedded lung sections were prepared as previously described 17 and probed with anti-P2ry13 219 
or anti-P2ry14 antibodies.  Photomicrographs were taken at 400x and 1000x magnification at room 220 
temperature and acquired using Olympus Image Analysis Software.   221 
 We performed a second set of experiments to test the hypothesis that P2ry13 or P2ry14 receptor 222 
activation could influence the release of alarmins, such as IL-33, and contribute to airway 223 
inflammation. Naïve mice were inoculated i.n. with saline, 10 nM 2-methyl-ADP (P2ry13 agonist), 10 224 
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nM UDP-glucose (P2ry14 agonist) or 10 nM ATP (agonist for all P2ry receptors, except P2ry6 and 225 
P2ry14), all in 50 uL. For comparison, three additional groups of mice were inoculated with 100 ug of 226 
HDM, 100 ug of cockroach extract (Blattella germanica) or 25 ug of Alternaria alternata extract. Two 227 
hours post-challenge, BALF was collected as described above and IL-33 levels measured by ELISA. 228 
Seventy-two hours post-challenge, BALF was again collected to obtain immune cell counts and stained 229 
for flow cytometry as described above.   230 
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RESULTS 231 
Application of EUGENE to results from a published asthma GWAS 232 
We applied our proposed gene-based test of association to a published asthma GWAS 14 including 233 
6,685 cases and 14,091 controls to identify genes with eQTLs collectively associated with disease risk. 234 
We tested the association with 17,190 genes (Figure 1) which were found to have cis-eQTLs 235 
(N=13,557), trans-eQTLs (N=315) or both (N=3,318), across 16 published eQTL studies, representing 236 
12 different cell types or tissues relevant to asthma (Table E2 in the Online Repository). 237 
Of the 17,190 genes tested, 48 genes were associated with asthma at an empirical FDR of 0.05  238 
(Table 1 and Figure 2). Of these, 31 (65%) were located within 1 Mb (or on the MHC region) of 239 
established risk variants for allergic disease (highlighted with a ‘+’ in Figure 2 and listed in Table E3 240 
in the Online Repository). For example, for TSLP18 (gene-based P=7x10-6), we identified six 241 
independent cis-eQTLs in five tissues, of which four were individually associated with asthma risk at 242 
P<0.05 (Table E4 in the Online Repository). Multiple genes within the same risk locus had 243 
significant associations with asthma: 12 in the MHC 15; 11 on 17q12 2; three on 2q12 15; and two on 244 
16p13 14. Some of these associations resulted from eQTLs being shared between neighboring genes, as 245 
observed for ORMDL3, GSDMB and ZPBP2 on 17q12 (Table E5 in the Online Repository), and for 246 
CLEC16A and SOCS1 on 16p13 (r2 between rs35441874 and rs7184491 [cf. Table E3] is 0.64). eQTL 247 
sharing could arise, for example, if an underlying causal variant disrupts the activity of a regulatory 248 
element that controls the expression of multiple genes. But that was not always the case; in the MHC 249 
region, the individual LTA eQTL that was most strongly associated with asthma (P=2x10-5) was in low 250 
LD (r2≤0.02) with the eQTLs for the other 11 significant MHC genes (Table E6 in the Online 251 
Repository). Similar results were observed for NEU1. Therefore, at least in the MHC region, the 252 
multiple significant associations observed were not entirely explained by eQTLs shared between genes.  253 
On the other hand, six (12%; LIMS1, AOAH, ZNF707, CLK3, SAFB and TINF2; ‘∆’ in Figure 254 
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2) of the 48 genes significant at an FDR of 0.05 were not located in established risk loci for asthma but 255 
the significant gene-based associations were (in most cases, entirely) driven by trans-eQTLs located in 256 
the MHC region or near ORMDL3 (Table E7 in the Online Repository). These include for example 257 
variant rs9268853, which is a trans-eQTL for CLK3 (P=7x10-17) in PBMCs19, SAFB (P=3x10-6) in 258 
whole-blood20 and AOAH in three tissues (best P=10-61, 19-21) (Table E8 in the Online Repository). 259 
This variant has also been found to be a cis-eQTL (P<5x10-8) for HLA-DQ and HLA-DR genes across 260 
multiple tissues (not shown). These results suggest that MHC and 17q12 variants might contribute to 261 
asthma risk not only by directly modulating the expression of nearby genes, but also by indirectly 262 
influencing the expression of genes in different chromosomes (eg. through cis-mediation 22). 263 
Of potential greater interest, 11 (23%) of the 48 significant genes were located in potential 264 
novel asthma risk loci and the gene-based associations were not driven by established allergy risk 265 
variants (‘○’ in Figure 2 and Table 1). As some of these genes might represent false-positive findings, 266 
we studied their association with asthma in an independent GWAS. 267 
 268 
Replication of the putative novel gene-based associations in an independent asthma GWAS 269 
To confirm the putative novel associations, we applied EUGENE to an independent GWAS of asthma 270 
with publicly available summary statistics 15. Based on results for 9,967 asthmatics and 15,301 271 
controls, four of the 11 genes selected for replication had a significant gene-based association (P<0.05; 272 
Table E9 in the Online Repository), when simulations show that on average the expected number of 273 
genes significant at this threshold by chance alone given multiple testing was 0.53 (SD=0.77).  274 
We then explored whether the discovery and replication associations for those four genes were 275 
consistent by comparing the direction of effect on disease risk for individual eQTLs. Overall, the 276 
direction of effect for most eQTLs of a given gene was the same between the two independent GWAS 277 
(Table E10 in the Online Repository). For example, of the seven eQTLs for USMG5 that were 278 
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individually associated with asthma risk in either study, for six the allele that increased asthma risk was 279 
the same (or was on the same haplotype) in both studies; one eQTL was not tested in the replication 280 
GWAS, and so the direction of effect could not be compared. Therefore, the association between 281 
asthma risk and these four genes is generally consistent at the individual eQTL level between the two 282 
independent GWAS. Henceforth, we refer to these four genes with a reproducible gene-based 283 
association with asthma as “putative novel asthma risk genes”. 284 
 285 
Contribution of cis- and trans-eQTLs to significant gene-based associations 286 
For three (P2RY13, P2RY14, USMG5) of the four putative novel risk genes, the gene-based association 287 
with asthma was entirely driven by cis-eQTLs. Most of these eQTLs were identified by eQTL studies 288 
of whole-blood expression levels (Table E11 in the Online Repository). For the fourth gene, 289 
B4GALT3, three cis (in neutrophils, blood and fibroblasts) and one trans (in blood) eQTL contributed 290 
to the association with asthma (Table E11 in the Online Repository). The latter (rs1668873) was 291 
located 44 Mb away on chromosome 1 and was previously reported to associate with mean platelet 292 
volume and count 23, 24. This variant is also a cis-eQTL for NUAK2 20, a nuclear transcriptional 293 
modulator that has been shown to induce the expression of B4GALT5 25, a galactosyltransferase related 294 
to B4GALT3 26. Therefore, these results suggest that both direct (cis-eQTLs) and indirect (via 295 
transcriptional modulators such as NUAK2) genetic effects on B4GALT3 expression might contribute to 296 
asthma risk. 297 
 298 
Genetically predicted direction of effect of gene expression on asthma risk 299 
To assess the direction of effect of gene expression on disease risk, we focused on the independent 300 
eQTLs for each gene that were individually associated with asthma in the discovery and/or replication 301 
GWAS. These variants had the greatest contribution to the significant gene-based tests. When we 302 
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compared the direction of effect for each eQTL between asthma risk and expression levels, we found 303 
that the allele associated with increased gene expression was also associated with increased asthma risk 304 
for all independent eQTLs of P2RY13 and P2RY14 (Table E11 in the Online Repository). The same 305 
pattern of results was observed for six of the seven eQTLs of USMG5; for example, the rs1163073:C 306 
allele that was associated with asthma risk (OR=1.09, P=0.0005), was associated with increased 307 
USMG5 expression in five different cell types or tissues (neutrophils, LCLs, skin, PBMCs and blood). 308 
These results suggest that in the tissues or cell types considered in our analysis, a genetically 309 
determined increase in gene expression for each of these four genes is associated with increased disease 310 
risk. For B4GALT3, there was no clear pattern across multiple eQTLs: of the four alleles associated 311 
with increased gene expression, two (in neutrophils and whole-blood) were associated with increased 312 
and two (in fibroblasts and whole-blood) with decreased disease risk. Such differences between eQTLs 313 
could arise, for example, if B4GALT3 has opposing functional effects on different cell types relevant to 314 
asthma (eg. activation in one, inhibition in another). Further studies are required to test this possibility. 315 
 316 
Functional studies in the mouse 317 
The four putative novel asthma risk genes identified in our genetic association analysis are involved in 318 
nucleotide synthesis (B4GALT3, USMG5) and nucleotide-dependent cell activation (P2RY13, P2RY14). 319 
Based on this observation, we hypothesise that genetic dysregulation of nucleotide signaling 320 
contributes to asthma risk. In depth functional experiments that comprehensively test this hypothesis 321 
were beyond the scope of this study. Nonetheless, we carried out two sets of experiments in the mouse 322 
to provide preliminary functional support for the involvement in allergic asthma for two of these four 323 
nucleotide-related genes: P2RY13 and P2RY14. Both are cell-surface receptors with known agonists, 324 
and so were well suited for functional studies. 325 
First, we used an established experimental model of acute allergic asthma16 to study P2ry13 and 326 
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P2ry14 expression in the lungs of C57BL/6 mice sensitized and subsequently challenged with house 327 
dust mite (HDM) allergen. In this model, mice develop granulocytic airway inflammation that has a 328 
predominant eosinophil contribution16. When considering overall lung expression, HDM challenge 329 
resulted in a significant increase in P2ry13 and P2ry14 expression, relative to control mice challenged 330 
with a saline solution (Figure 3A). To understand which lung cell types contributed to this increase in 331 
gene expression, we used flow cytometry to measure protein expression in airway epithelial cells 332 
(AECs) and major immune cell types collected through bronchoalveolar lavage. There was widespread 333 
expression of both receptors in AECs, both at baseline and after HDM challenge (Figure 3B and 3C). 334 
Most eosinophils collected in BALF after HDM challenge stained positive for both receptors (Figure 335 
3D); expression in neutrophils was also high (Figure 3E). Lymphocytes and dendritic cells had low 336 
expression of both receptors (Figure E2 in the Online Repository).  337 
 Secondly, given the high level of P2ry13 and P2ry14 expression observed in AECs at baseline 338 
(ie. in the absence of allergen challenge), and the previously reported pro-inflammatory effect of the 339 
respective agonists (eg. 27, 28), we postulated that receptor activation could promote airway 340 
inflammation by inducing the release of alarmins. To test this possibility, we collected BALF from 341 
naïve mice 2 and 72 hours after intra-nasal challenge with saline, ADP (selective P2ry13 agonist) or 342 
UDP-glucose (selective P2ry14 agonist). At 2 hours post challenge, BALF levels of the alarmin IL-33 343 
were significantly greater in mice exposed to the receptor agonists than in control mice (Figure 4A). 344 
Of note, nucleotide-induced IL-33 levels were comparable to allergen-induced IL-33 levels, indicating 345 
that both ADP and UDP-glucose are sufficient to induce IL-33 release. Furthermore, 72 hours after 346 
challenge, the number of BALF eosinophils and lymphocytes were significantly higher in agonist-347 
treated mice (Figure 4B and 4C), but this was not the case for neutrophils, dendritic cells and 348 
monocytes (Figure E3 in the Online Repository). These results demonstrate that selective agonists of 349 
P2ry13 and P2ry14 can promote airway inflammation, even in the absence of allergen stimulation. 350 
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DISCUSSION 351 
Dysregulation of gene expression is thought to be a common mechanism by which genetic variants can 352 
influence cellular function and, ultimately, variation in human traits and disease risk. This proposition 353 
is supported by the observation that eQTLs are more likely to be trait-associated than random variants 354 
18
 and was the motivation for the gene-based approach developed in this study.  355 
EUGENE has some advantages when compared to other gene-based association approaches, of 356 
which we highlight three: VEGAS 9, PrediXcan 12 and TWAS 13. When compared to VEGAS, 357 
EUGENE avoids the requirement to use an arbitrary distance (same for all genes) from the known gene 358 
boundaries to define which SNPs to include in the gene-based analysis. If the distance is too small (eg. 359 
+/-5 kb), then the contribution of important more distantly located eQTLs might be missed, while a 360 
large distance (eg. +/- 1 Mb) could result in testing a large number of variants, many of which are likely 361 
to be unrelated to gene expression/function; in both cases, the power to detect a significant gene-based 362 
association is reduced. Also, because the analysis in EUGENE is restricted to variants previously 363 
shown to influence gene expression, whether in cis or in trans, a significant gene-based trait association 364 
directly implies that genetically-determined differences in gene expression contribute to trait variation. 365 
On the other hand, when compared to the recently described PrediXcan approach 12, the main 366 
advantage of EUGENE is that it is applicable to GWAS summary statistics, which are typically easier 367 
to share than data sets with individual level genetic data. TWAS13, which is conceptually very similar to 368 
PrediXcan, is applicable to summary statistics but its current release only includes weights for a 369 
relatively small number of genes obtained from three eQTL studies, although this is likely to increase 370 
in the future. Another major difference when compared to both of these approaches is that with 371 
EUGENE, eQTLs identified in transcriptome studies of different cell types (and/or upon cell 372 
stimulation) can be included in the same association analysis, all contributing with equal weight to the 373 
gene-based statistic. This might be important for traits or diseases for which multiple cell types or 374 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
tissues are known to play a role in the underlying pathophysiology. In the PrediXcan and TWAS 375 
approaches, the weights assigned to different eQTLs in the model used to predict gene expression 376 
levels are based on the effect (eg. regression coefficient) of those variants on expression levels 377 
measured in a single reference transcriptome data set. The extent to which those weights remain 378 
appropriate (ie. yield good prediction) if the reference transcriptome and target data sets are very 379 
different (eg. in age composition) is unclear. A disadvantage of EUGENE is that the direction of effect 380 
between gene expression and disease risk (or trait variation) is not directly inferred. To do so with the 381 
EUGENE approach, the effect of individual eQTLs that contribute to the gene-based test needs to be 382 
compared ad-hoc between the transcriptome and trait GWAS. These eQTLs also provide a specific 383 
small group of variants to test in validation studies. Lastly, EUGENE (but not the other three 384 
approaches) estimates FDR thresholds empirically, taking into account the LD between eQTLs of the 385 
same or different genes. This is important to account for multiple testing. 386 
 When we applied EUGENE to a published GWAS of asthma, we identified 48 genes with a 387 
significant gene-based association at an FDR of 0.05, including 11 associations that were not driven by 388 
established genetic risk variants for allergic disease. For four of these genes (B4GALT3, USMG5, 389 
P2RY13 and P2RY14), the association was nominally significant in an independent asthma GWAS and 390 
so we refer to these as putative novel asthma risk genes. 391 
 B4GALT3 encodes the widely-expressed enzyme β-1,4-galactosyltransferase III that catalyzes 392 
the transfer of galactose from UDP-galactose to N-acetylglucosamine, to form N-acetyllactosamine and 393 
UDP 26, 29. How variation in B4GALT3 expression might contribute to asthma risk is unclear, but 394 
potential mechanisms include activation of β1 integrin 30, which is important in the initiation of T-cell 395 
inflammatory responses 31, or by influencing extracellular release of UDP-galactose 32, a P2RY14 396 
agonist. 397 
 USMG5 encodes a small subunit of ATP synthase 33, an enzyme responsible for ATP synthesis in 398 
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the mitochondria. USMG5 knockdown in HeLa cells causes the loss of ATP synthase, resulting in lower 399 
ATP synthesis and slower cell growth 34. In CD4+ T-cells, mitochondria produce the ATP that is rapidly 400 
released into the extracellular space upon cell stimulation 35. In turn, this ATP establishes an autocrine 401 
feedback through purinergic receptors that is essential for proper T-cell activation 36. Given these 402 
observations, we speculate that genetically-determined increased USMG5 expression results in 403 
increased mitochondrial production of ATP, increased extracellular ATP release and increased T-cell 404 
activation. In turn, this would translate into an increased risk of asthma. ATP synthase has also been 405 
detected at the surface of different cell types 37, where it is thought to play different physiological roles, 406 
for example, HDL endocytosis in hepatocytes via P2RY13 activation 38 and non-conventional T-cell 407 
activation 39. Whether USMG5 associates with membrane ATP synthase, and so could potentially 408 
influence its ectopic roles, remains to be determined. 409 
P2RY13, also known as GPR86 or GPR94, is a purinergic receptor highly expressed in the 410 
immune system, lung and skin, but also in the brain 40-42; it displays a significant homology with the 411 
nearby P2RY12 and P2RY14 genes, sharing 48 and 45% amino acid identity 40. P2RY13 is strongly 412 
activated by ADP 40, a degradation product of ATP. Airway epithelial goblet cells are a major source of 413 
extracellular ADP, which is released as a co-cargo molecule from mucin-containing granules 43. In turn, 414 
ADP has been shown to enhance antigen-induced degranulation in mast cells, through a P2RY13-415 
dependent mechanism 27. ADP has also been reported to promote IL-6 release from keratinocytes 42, 416 
inhibit TNF-alpha and IL-12 production by mature DCs 44 and promote chemotaxis of immature DCs 417 
45; however, these studies did not specifically test if the observed ADP effects were mediated by 418 
P2RY13. Results from our genetic association analyses indicate that a genetically-determined increase 419 
in P2RY13 expression increases asthma risk, which is consistent with the pro-inflammatory effect 420 
suggested for ADP and P2RY13 by these functional studies.  421 
P2RY14, also known as GPR105, encodes a G protein-coupled receptor that is potently and 422 
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selectively activated by UDP-sugars, especially UDP-glucose 46. UDP-glucose is thought to be an 423 
extracellular pro-inflammatory mediator 47, constitutively released by different cell types including 424 
airway epithelial cells 48. Importantly, infection with respiratory syncytial virus (RSV) or treatment 425 
with IL-13 significantly increases UDP-glucose release by airway epithelial cells 49, and this coincides 426 
with increased mucus secretion 50. Known pro-inflammatory effects of UDP-glucose acting through 427 
P2RY14 include inhibition of TLR9-dependent IFN-alpha production 51, increased chemotaxis of 428 
neutrophils 52, induction of mast cell degranulation 53, production of IL-8 28, 54 and STAT3-dependent 429 
epidermal inflammation 55. A small molecule antagonist for P2RY14 was recently developed and 430 
shown to effectively block chemotaxis of freshly isolated human neutrophils 56. Of note, plasma UDP-431 
glucose levels are elevated in mice fed a high-fat diet 57, which raises the possibility that obesity might 432 
contribute to chronic P2RY14 activation and, in that way, increase asthma risk and/or severity. Studies 433 
that investigate this possibility are underway. 434 
  When we studied the expression of both P2ry13 and P2ry14 in mice, we found that both genes 435 
were highly expressed in AECs, both at baseline and after allergen challenge. High expression was also 436 
observed in infiltrating eosinophils after challenge and, to a smaller extent, neutrophils and monocytes. 437 
High expression in AECs suggested that receptor activation could contribute to airway inflammation 438 
even in the absence of allergen stimulation. This was indeed what we observed when naïve mice were 439 
challenged intra-nasally with either ADP or UDP-glucose: 72 hours after challenge, the numbers of 440 
BALF eosinophils were significantly increased when compared to control mice. Interestingly, 441 
eosinophil influx into the airways was preceded by a significant increase in the levels of the alarmin IL-442 
33. The effect of both receptor agonists on IL-33 release was comparable in magnitude to that observed 443 
with allergens known to have a potent effect on IL-33 production, namely the fungus Alternaria 444 
alternata 58. These results demonstrate that activation of P2ry13 and P2ry14, in addition to P2y2 58, can 445 
strongly induce IL-33 release in mice. Interestingly, P2ry13 expression was observed in the nuclei of 446 
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AECs after allergen challenge. Given that IL-33 is constitutively stored in the nuclei of AECs 59, it is 447 
possible that intracellular activation of P2ry13 expressed on the nuclear membrane plays a role in 448 
allergen-induced IL-33 release. 449 
In conclusion, our genetic findings establish an association between asthma risk and genes 450 
involved in nucleotide synthesis (B4GALT3, USMG5) and nucleotide-dependent cell activation 451 
(P2RY13, P2RY14). In mice, in vivo activation of P2ry13 and P2ry14 induced IL-33 release and 452 
subsequent eosinophilic airway infiltration. These observations suggest that genetic dysregulation of 453 
nucleotide signaling contributes to the risk of asthma (allergic and, potentially, also non-allergic) and 454 
other related conditions; studies that test this possibility are now warranted. Our results also show that 455 
re-analysis of published GWAS with a gene-based test that exclusively focuses on documented eQTLs 456 
has the potential to identify novel associations.  457 
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TABLES 461 
 462 
Table 1. Forty eight genes with a significant (FDR < 5%) association with asthma risk in the Ferreira et 463 
al. 14 GWAS. 464 
Gene Position N 
eQTLs 
N eQTLs 
tested 
N eQTLs  
with 
P<0.05 
Best individual eQTL EUGENE 
P-value 
Potential 
novel 
associationa SNP P-value 
HLA-DQB1 6:32627244 78 26 15 rs1063355 1.8 x 10-13 <10-6 No 
GSDMB 17:38060848 15 11 5 rs2952140 1.2 x 10-8 <10-6 No 
LIMS1 2:109150857 15 14 4 rs1063355 1.8 x 10-13 <10-6 No* 
TLR1 4:38792298 9 6 3 rs12233670 1.4 x 10-11 <10-6 No 
ORMDL3 17:38077294 19 14 5 rs2952140 1.2 x 10-8 <10-6 No 
IKZF3 17:37921198 9 7 3 rs7207600 4.5 x 10-7 <10-6 No 
IL18RAP 2:103035149 18 16 6 rs13018263 5.0 x 10-6 <10-6 No 
CLEC16A 16:11038345 4 4 2 rs35441874 2.9 x 10-8 <10-6 No 
ZPBP2 17:38024417 2 2 1 rs9916765 1.9 x 10-9 <10-6 No 
GRB7 17:37894180 2 1 1 rs14050 1.4 x 10-7 <10-6 No 
TINF2 14:24708849 4 4 2 rs3135006 1.7 x 10-6 <10-6 No* 
TAP2 6:32789610 48 36 11 rs2858312 1.9 x 10-5 2.0 x 10-6 No 
TAP1 6:32812986 13 12 4 rs6928482 2.0 x 10-8 2.0 x 10-6 No 
HSPA1B 6:31795512 13 13 6 rs13215091 4.7 x 10-4 2.0 x 10-6 No 
TSLP 5:110405760 6 6 4 rs17132582 3.2 x 10-4 2.0 x 10-6 No 
DYNC1H1 14:102430865 6 5 2 rs4906262 1.1 x 10-5 2.0 x 10-6 Yes 
HLA-DRB1 6:32546546 97 46 18 rs3806156 1.4 x 10-4 4.0 x 10-6 No 
IL18R1 2:102927989 11 11 5 rs6751967 3.2 x 10-6 4.0 x 10-6 No 
SOCS1 16:11348262 7 6 5 rs7184491 3.5 x 10-6 4.0 x 10-6 No 
CISD3 17:36886488 4 4 2 rs2941503 1.6 x 10-7 5.0 x 10-6 No 
PGAP3 17:37827375 2 2 1 rs903502 1.5 x 10-6 6.0 x 10-6 No 
IL1RL2 2:102803433 2 2 1 rs9646944 6.7 x 10-7 9.0 x 10-6 No 
CLK3 15:74890841 2 2 1 rs9268853 1.8 x 10-6 9.0 x 10-6 No* 
SMAD3 15:67356101 7 7 2 rs17293632 2.0 x 10-7 1.1 x 10-5 No 
SAFB 19:5623046 2 2 1 rs9268853 1.8 x 10-6 1.1 x 10-5 No* 
P2RY13 3:151044100 8 8 5 rs9877416 1.2 x 10-4 1.2 x 10-5 Yes 
AOAH 7:36552456 26 21 3 rs9268853 1.8 x 10-6 1.3 x 10-5 No* 
SLC44A4 6:31830969 2 2 1 rs9275141 1.1 x 10-6 1.3 x 10-5 No 
STARD3 17:37793318 7 3 1 rs2941503 1.6 x 10-7 1.5 x 10-5 No 
LTA 6:31539831 16 13 5 rs2442752 1.5 x 10-5 1.6 x 10-5 No 
MED24 17:38175350 5 5 2 rs7502514 4.8 x 10-5 1.7 x 10-5 No 
HIBADH 7:27565061 14 12 6 rs6951856 9.6 x 10-5 2.9 x 10-5 Yes 
P2RY12 3:151055168 6 6 4 rs17282940 7.0 x 10-5 3.0 x 10-5 Yes 
NR1D1 17:38249040 5 4 2 rs12150298 2.8 x 10-6 3.0 x 10-5 No 
ZNF707 8:144766622 9 8 3 rs17609240 1.5 x 10-6 4.2 x 10-5 No* 
TOP2A 17:38544768 1 1 1 rs2102928 4.1 x 10-5 4.9 x 10-5 No 
HLA-DRB6 6:32520490 60 13 6 rs522254 6.3 x 10-4 5.4 x 10-5 No 
REEP3 10:65281123 6 4 2 rs7898489 9.1 x 10-6 6.1 x 10-5 Yes 
PTCSC3 14:36605314 2 2 2 rs7148603 1.8 x 10-4 6.5 x 10-5 Yes 
P2RY14 3:150929905 13 12 5 rs10513393 1.1 x 10-4 7.2 x 10-5 Yes 
HLA-DQA1 6:32595956 79 29 9 rs504594 1.7 x 10-5 8.1 x 10-5 No 
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ACO2 22:41865129 3 3 2 rs960596 1.3 x 10-4 9.4 x 10-5 Yes 
HCP5 6:31368479 23 22 4 rs2071595 6.7 x 10-6 9.6 x 10-5 No 
NEU1 6:31825436 8 8 5 rs9267901 9.1 x 10-4 9.8 x 10-5 No 
MICB 6:31462658 41 30 9 rs9268764 3.3 x 10-5 1.2 x 10-4 No 
B4GALT3 1:161141100 10 9 3 rs1668873 1.5 x 10-3 1.2 x 10-4 Yes 
USMG5 10:105148798 16 14 4 rs1163073 4.9 x 10-4 1.5 x 10-4 Yes 
F12 5:176829141 3 3 2 rs4976765 1.7 x 10-3 1.5 x 10-4 Yes 
 
465 
a
 Potential novel genetic associations with asthma (highlighted in grey) are those for which the gene-based association was 466 
not driven by eQTLs located in known allergy risk loci. Known allergy loci are defined as those that contain a variant 467 
reported to be associated with asthma or other allergic diseases with P<5x10-8 in published GWAS. * Genes not located in 468 
an asthma risk locus but for which the gene-based association was driven by trans-eQTLs in LD with allergy risk variants 469 
(see Table E7 for more details).  470 
  471 
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FIGURE LEGENDS 472 
 473 
Figure 1. Outline of analytical procedure.  474 
 475 
Figure 2. Summary of association results obtained for 17,190 genes by applying the proposed 476 
gene-based test of association to a published asthma GWAS14. The red horizontal line shows the P-477 
value threshold corresponding to an empirical FDR of 5% (P=1.9x10-4). Forty eight genes exceeded 478 
this threshold, including (1) 31 genes located in established risk loci for allergic disease (denoted by 479 
‘+’; gene name shown in black font); (2) six genes located in new risk loci but with a gene-based 480 
association that was driven by trans-eQTLs located in the MHC or near ORMDL3 (denoted by ‘∆’); 481 
and (3) 11 genes with a gene-based association that was not driven by eQTLs located in established 482 
allergy risk loci (denoted by ‘○’), including four (green font) for which the association replicated in an 483 
independent GWAS15. The y-axis represents the –log10 of the simulation-derived gene-based P-value, 484 
which accounts for the residual LD between eQTLs of a given gene. The P-value was based on up to 1 485 
million simulations, and so it could not exceed a P=10-6 (dashed grey line).  486 
 487 
Figure 3. Expression levels of P2ry13 and P2ry14 in lung of C57Bl/6 mice sensitized and then 488 
challenged with a saline solution or a house dust mite extract. (A) Overall gene expression in lung. 489 
Expression levels were normalized to Hprt and are expressed as fold-change over saline challenge 490 
group. Results show mean +/- SD in each group. * Wilcoxon rank sum test P < 0.005 when comparing 491 
HDM and saline groups. (B, D and E) Expression of P2ry13 and P2ry14 based on flow cytometry 492 
analysis in lung epithelial cells, or eosinophils and neutrophils collected in BALF after saline or HDM 493 
challenge. (C) Expression of P2ry13 and P2ry14 in lung sections of mice challenged with saline or 494 
HDM.  495 
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 496 
Figure 4. In vivo exposure to P2ry13 and P2ry14 receptor agonists in naïve C57Bl/6 mice. Mice 497 
were challenged with either vehicle, one of three allergens (HDM, CRE, Alt) or one of three 498 
nucleotides (ATP, UPD-glucose, ADP), and euthanized 2 and 72 hours after challenge. (A) IL-33 499 
expression in bronchoalveolar lavage fluid (BALF) collected 2 hours post challenge. Total number of 500 
eosinophils (B) and lymphocytes (C) recruited to the BALF at 72 hours post challenge, based on flow 501 
cytometry analysis. Veh: vehicle. HDM: house dust mite. CRE: cockroach. Alt: alternaria. 502 
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Supplementary Methods 
 
EUGENE approach 
The proposed gene-based approach includes four steps, which for a given gene briefly consists of: (1) 
identifying variants that influence gene expression; (2) extracting association results for these 
regulatory variants from a disease or trait GWAS of interest and then calculate a gene-based statistic Q 
– this represents the aggregate evidence for association in that GWAS across all regulatory variants of 
that gene; and perform simulations using individual-level genetic data to estimate (3) the statistical 
significance of Q and (4) false discovery rate (FDR) thresholds to empirically account for multiple 
testing. These steps are described in more detail below; the software and input files required to run 
EUGENE are freely available at https://genepi.qimr.edu.au/staff/manuelF. 
 Step 1: generate a list of independent single nucleotide polymorphisms (SNPs) that are 
associated with variation in gene expression levels (ie. expression quantitative trait loci, eQTLs). First, 
a database of eQTLs associated with gene expression levels in cis (located < 1 Mb from gene 
boundaries) or trans (> 1 Mb away or in a different chromosome) was created from 16 published 
transcriptome GWAS that analysed 12 tissues or cell types relevant for asthma (Table E2). Other 
biologically relevant marks of gene regulation (eg. CpG methylation) will be made available as studies 
with greater power to identify such effects are published. Second, for each gene, the eQTLs in this 
database were reduced to a sub-set with linkage disequilibrium (LD) r2<0.1, using the clump procedure 
implemented in PLINK 1. We refer to these as “independent eQTLs” for a given gene; more stringent 
LD thresholds (eg. low |D’|) or conditional association analyses could be used to generate a more 
conservative set of independent eQTLs.  The average number of independent eQTLs per gene was 5.1 
(median=3, maximum=97, IQR=5; Figure E1). Third, we used data from the 1000 Genomes project 2 
to identify all known proxies (r2>0.8) for each independent eQTL. This is important because if a 
specific eQTL is not tested in a given GWAS, a proxy SNP might still be available and could instead be 
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used for analysis. A file containing independent eQTLs for each gene, and their respective proxy SNPs, 
is required to run EUGENE and is available at https://genepi.qimr.edu.au/staff/manuelF. Files 
containing eQTLs in tissues relevant for other diseases or traits are also available but were not analysed 
in this study. 
 Step 2: calculate a gene-based association statistic Q for each gene based on results from 
individual SNPs in a GWAS of interest. The 1-df disease association chi-square statistic q for each of k 
independent eQTLs of gene i is extracted from the trait or disease GWAS of interest. If a specific eQTL 
was not tested, the most correlated proxy SNP available (with r2>0.8) is used. Then, for each gene i, the 
overall statistical evidence for association between all k independent eQTLs tested for that gene and the 
trait or disease of interest is simply calculated as  = ∑ 	 , that is, the sum of the individual chi-
square statistics across all independent eQTLs tested.  
Step 3: perform simulations using individual-level genetic data to estimate the statistical 
significance of Qi. When eQTLs of the same gene are in linkage equilibrium (eg. r2 ~ 0), a measure of 
statistical significance of Qi could be obtained from a chi-square distribution with k degrees of 
freedom. In this scenario, this asymptotic P-value is not inflated under the null hypothesis of no 
association (not shown). However, as the LD between eQTLs increases, the asymptotic P-value 
becomes inflated under the null: for example, using an r2 threshold of 0.1 to define independent eQTLs, 
on average (across 1,000 simulated GWAS) 5.4% of genes had a significant asymptotic P-value at 
P<0.05, a 1.08-fold increase over the 5.0% nominal expectation. This is because the assumption of 
statistical independence between eQTLs of a gene is not strictly achieved with that r2 threshold. For 
this reason, we do not calculate an asymptotic P-value for Qi, but instead estimate an empirical P-value 
that accounts for the residual LD between eQTLs. To estimate the empirical P-value for Qi, we analyze 
the association between gene i and a dummy trait with a normal distribution in 379 unrelated 
individuals of European descent with genotype data available through the 1000 Genomes Project 2. 
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Other GWAS datasets with available individual level genetic data can be used in this step, including 
those of non-European ancestry. Using a GWAS dataset with a larger sample size (>4,000 individuals) 
did not influence the performance of this step (not shown), and so we used data from the 1000 
Genomes Project given its availability to other researchers and decreased computation time. Briefly, in 
this analysis we (1) simulate a normally-distributed phenotype for the genotyped individuals under the 
null hypothesis of no association with any eQTLs of gene i; (2) test this phenotype for association with 
each eQTL – any significant associations in this analysis are due to chance only; and (3) calculate a 
gene-based association statistic Q as described above (Qi_null). This procedure is repeated a large 
number of times (eg. 1 million simulations). The empirical P-value for Qi is then calculated as the 
proportion of simulations for which Qi_null ≥ Qi.  
Step 4: perform simulations using individual-level genetic data to estimate FDR thresholds to 
account for multiple testing. Typically, EUGENE will be used to test the association between a trait and 
many genes, and so it is important to address the impact of multiple testing on false positive findings. 
To achieve this, we adopt the false-discovery rate (FDR) quantity advocated by Storey and Tibshirani 3. 
For a given threshold t (eg. 0.05), FDR is approximated by the expected number of genes with a P-
value ≤ t when the null is true (E[Ft]), divided by the expected total number of genes with a P-value ≤ t 
(E[St]). A simple estimate of E[St] is the observed St, that is, the number of genes with a P-value ≤ t. To 
estimate E[Ft], we use simulations generated under the null using individual-level genetic data as 
described above. Specifically, we (1) simulate a normally-distributed phenotype for the genotyped 
individuals under the null hypothesis of no association with any eQTLs of all genes tested; (2) test this 
phenotype for association with all eQTLs analysed across all genes; and (3) calculate a gene-based 
association statistic Q and its empirical P-value for each gene tested as described above. This procedure 
is repeated 100 times. For each of these 100 simulations, we count the number of genes significant at 
different P-value thresholds t (10-6 down to 0.1); for a given t, the average count across 100 simulations 
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is taken as an estimate of E[Ft]. For each P-value threshold t considered, we estimate FDRt as E[Ft] / 
E[St]; based on these FDRt, we determine the minimum P-value threshold t that would result in an FDR 
of 0.05. At this P-value threshold t, 5% of genes called significant are estimated to be false-positives. 
As a concrete example, in the discovery GWAS described in the main text, the P-value threshold that 
resulted in an FDR of 0.05 was 1.9x10-4. At this threshold, 48 genes were associated with asthma risk, 
of which about 3 (48 x 0.05) are expected to be false-positives due to multiple testing. 
 
Assessment of the type-1 error rate of EUGENE 
To assess whether the proposed gene-based test had an appropriate type-I error rate, we (1) simulated a 
dummy normally-distributed phenotype for 379 genotyped individuals, as described above, and tested 
its association with all available SNPs – that is, we simulated results from a GWAS under the null 
hypothesis of no association; (2) applied EUGENE to the resulting summary statistics and retained the 
gene-based P-value for each of 17,190 genes; and (3) repeated steps (1) and (2) to simulate and analyse 
results for 1,000 GWAS generated under the null. The type-I error rate for a given nominal α was taken 
as the mean (across the 1,000 null GWAS) proportion of genes with a significant association at that α 
level. 
 
Functional studies in the mouse 
Experiment set 1: Expression of P2ry13 and P2ry14 in a mouse model of acute experimental asthma. 
We used an established mouse model of acute allergic asthma 4 to identify the cell types that express 
P2ry13 and P2ry14 in the context of allergen-induced airway inflammation. Experiments were 
performed in accordance with the Animal Care and Ethics Committees of the University of Queensland 
(Brisbane, Australia). Briefly, two groups of eight- to twelve-week old wild-type C57Bl/6 mice were 
lightly anesthetized with isoflurane and sensitized intranasally with either saline solution (group 1) or 
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100 µg of HDM extract (Dermatophagoides pteronyssinus; Greer Laboratories, Lenoir, NC, USA; 
group 2) on day 0. Subsequently, mice were challenged with either saline (group 1) or 5 µg of HDM 
(group 2) at day 14, 15, 16 and 17 and sacrificed 3 hours later. In this model, mice challenged with 
HDM develop all the hallmark features of asthma, including airway hyperresponsiveness, mucous cell 
hyperplasia and granulocytic airway inflammation 4.  
To measure overall gene expression in lung, total RNA was isolated from the left lung with 
TriReagent solution (Ambion) and phenol-chloroform extraction. DNAse digestion was performed with 
Turbo DNAse (Ambion), according to the manufacturer’s instructions. Reverse transcription was 
performed using M-MLV reverse transcriptase and random primers (Invitrogen). Quantitative real-time 
PCR was performed with SYBR Green (Life Technologies) and the primers described in Table E13. 
Expression values were normalized to Hprt and expressed as fold change over saline mice.  
To identify individual cell types in the lung expressing P2ry13 and P2ry14, a bronchoalveolar 
lavage was performed by flushing the lungs with 600 ul of ice-cold PBS. The recovered fluid was 
centrifuged (1600 rpm for 5 minutes) and the bronchoalveolar lavage fluid (BALF) stored at -80oC 
until analysis. Lung lobes were dissected and single cell suspensions prepared by mechanical digestion 
through a cell strainer as described 4. Following red blood cell lysis with Gey’s lysis buffer, cells were 
counted then incubated with Fc block for 30 minutes at 4°C.  Cells were then stained with anti-P2ry13 
(Acris Antibodies) or anti-P2ry14 (Acris Antibodies), followed by appropriate fluorescently-labelled 
secondary.  Then cells were stained with the following fluorescently labeled antibodies: FITC 
conjugated Ly6G (clone 1A8), PerCP-Cy5.5 conjugated CD11b (clone M1/70), AF647 conjugated 
Siglec F (clone E50-2440) (all BD Biosciences), BV570 conjugated Ly6C (clone HK1.4), BV785 
conjugated CD11c (clone N418), AF488 conjugated Epcam (CD326) (clone G8.8), BV421 conjugated 
CD45 (clone 30-F11) (all Biolegend), PE conjugated B220 (clone RA3-6B2) and CD3ε (clone145-
2C11), APC-eFluor 780 or PE conjugated MHCII (clone M5/114.15.2) (all eBioscience). Cells were 
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enumerated using a BD LSR Fortessa cytometer (BD Biosciences, San Jose, CA, USA) and the data 
analyzed with FACSDiva v8 (BD Biosciences) and FlowJo v8.8 (Treestar). 
To assess expression in airway epithelial cells, paraffin-embedded lung sections were prepared 
as previously described 5. Lung sections were pretreated with 10% normal goat serum for 30 min.  
Sections were probed with anti-P2ry13 (Acris Antibodies) or anti-P2ry14 (Acris Antibodies) overnight 
at 4°C.  Following incubation with appropriate secondary antibodies, immunoreactivity was developed 
with Fast Red (Sigma-Aldrich) and counterstained with Mayer’s hematoxylin.  Photomicrographs were 
taken at 400x and 1000x magnification using an Olympus BX-51 microscope with an Olympus DP-72 
camera at room temperature and acquired using Olympus Image Analysis Software.   
 
Experiment set 2: Effect of in vivo exposure to P2ry13 and P2ry14 agonists on airway inflammatory 
profile in mice. Given the high expression of both receptors on airway epithelial cells in naïve mice, we 
hypothesized that receptor activation could influence the release of alarmins, such as IL-33, and 
contribute to airway inflammation. To test this possibility, 6 naïve mice per group were inoculated via 
intra nasal (i.n.) route with saline, 10 nM 2-methyl-ADP (P2ry13 agonist; R&D), 10 nM UDP-glucose 
(P2ry14 agonist; Abcam) or 10 nM ATP (agonist for all P2ry receptors, except P2ry6 and P2ry14; 
Sigma), all in 50 uL (ie. total dose of 0.5 pmol for all nucleotides). For comparison, three additional 
groups of mice were inoculated with 100 ug of HDM (source as above), 100 ug of cockroach extract 
(Blattella germanica, Greer Laboratories) or 25 ug of alternaria alternata extract (Alternaria tenuis, 
Greer Laboratories). Two hours post-challenge, BALF was collected as described above and IL-33 
levels measured by ELISA (R&D Systems). Seventy-two hours post-challenge, BALF was again 
collected to obtain immune cell counts and stained for flow cytometry as described above. 
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E Tables 
 
Table E1. Type-I error rate of EUGENE.  
Nominal 
type-I error 
rate (α) 
Observed 
type-I error 
rate 
0.1000 0.09818 
0.0500 0.04873 
0.0100 0.00950 
0.0050 0.00468 
0.0010 0.00090 
0.0005 0.00043 
 
The observed type-I error rate corresponds to the average proportion of genes (out of 17,190 tested) with an association P-
value ≤ α, when analyzing 1,000 GWAS simulated under the null hypothesis of no association. 
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Table E2. Number of genes with significant cis (+/- 1 Mb) eQTLs in published GWAS of gene 
expression that analyzed tissues relevant to asthma.  
N Genes Reference Tissue Experiment/eQTL type 
11047 6 Whole-blood  
10142 7
 
Whole-blooda  
9271 8 Lung  
8752 9 Fibroblasts  
7461 10 Monocytes  
7294 11 LCLs  
7225 9 Lung  
6823 10 B-cells  
6783 9 Whole-blood  
5184 12 PBMCs  
3175 13 Neutrophils  
2954 9 LCLs  
2754 9 Spleen  
2098 14 Fibroblasts  
2097 14 LCLs  
1992 14 T-cells  
1732 15 LCLs  
1133 16 LCLs  
1074 17 Monocytes Baseline 
992 15 Skin  
916 17 Monocytes LPS 
889 6 Whole-blood Splice eQTLs 
831 18 Neutrophils  
528 6 Whole-blood ASE eQTLs 
508 19 Skin Normal 
484 20 Small airways  
404 19 Skin Uninvolved 
381 19 Skin Lesional 
313 21 LCLs  
81 17 Monocytes Differential 
 
a
 Including all cis SNP-gene associations significant at FDR of 0.5 (listed in file 2012-12-21-
CisAssociationsProbeLevelFDR0.5.txt released with the original publication). 
LCLs: lymphoblastoid cell lines. PBMCs: peripheral blood mononuclear cells. 
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Table E3. Thirty one genes associated with asthma at an empirical FDR of 0.05 and located within 1 
Mb (or on the MHC region) of established risk variants for allergic disease. 
 
Gene N 
eQTLs 
cis-eQTLs  trans-eQTLs 
EUGENE 
P-value N 
Tested 
N with 
P<0.05 
Best individual eQTL  N 
Tested 
N with 
P<0.05 
Best individual eQTL 
SNP P-value  SNP P-value 
Chromosome 2q12 
IL1RL2 2 2 1 rs9646944 6.7E-07  0 0 NA NA 4.0E-6 
IL18R1 11 11 5 rs6751967 3.2E-06  0 0 NA NA 7.0E-6 
IL18RAP 18 16 6 rs13018263 5.0E-06  0 0 NA NA <1E-6 
Chromosome 4p14 
TLR1 9 6 3 rs12233670 1.4E-11  0 0 NA NA <1E-6 
Chromosome 5q22 
TSLP 6 6 4 rs17132582 3.2E-04  0 0 NA NA 7.0E-6 
Chromosome 6p21 
HCP5 23 20 4 rs2071595 6.7E-06  2 0 rs891140 0.5289 9.1E-5 
MICB 41 28 8 rs9268764 3.3E-05  2 1 rs647316 0.0249 1.1E-4 
LTA 16 13 5 rs2442752 1.5E-05  0 0 NA NA 2.9E-5 
HSPA1B 13 13 6 rs13215091 4.7E-04  0 0 NA NA 3.0E-6 
NEU1 8 7 5 rs9267901 9.1E-04  1 0 rs975666 0.4341 1.1E-4 
SLC44A4 2 2 1 rs9275141 1.1E-06  0 0 NA NA 2.0E-5 
HLA-DRB6 60 13 6 rs522254 6.3E-04  0 0 NA NA 5.8E-5 
HLA-DRB1 97 16 7 rs9272230 5.2E-04  30 11 rs3806156 0.0001 5.0E-6 
HLA-DQA1 79 23 5 rs504594 1.7E-05  6 4 rs1235162 0.0044 8.1E-5 
HLA-DQB1 78 22 12 rs3129719 2.6E-06  4 3 rs1063355 1.8E-13 <1E-6 
TAP2 48 36 11 rs2858312 1.9E-05  0 0 NA NA 3.0E-6 
TAP1 13 11 3 rs6928482 2.0E-08  1 1 rs653178 0.0363 <1E-6 
Chromosome 15q22 
SMAD3 7 7 2 rs17293632 2.0E-07  0 0 NA NA 1.7E-5 
Chromosome 16p13 
CLEC16A 4 4 2 rs35441874 2.9E-08  0 0 NA NA 2.0E-6 
SOCS1 7 5 5 rs7184491 3.5E-06  1 0 rs1219648 0.141 <1E-6 
Chromosome 17q12 
CISD3 4 4 2 rs2941503 1.6E-07  0 0 NA NA <1E-6 
STARD3 7 3 1 rs2941503 1.6E-07  0 0 NA NA 2.7E-5 
PGAP3 2 2 1 rs903502 1.5E-06  0 0 NA NA 1.4E-5 
GRB7 2 1 1 rs14050 1.4E-07  0 0 NA NA <1E-6 
IKZF3 9 7 3 rs7207600 4.5E-07  0 0 NA NA <1E-6 
ZPBP2 2 2 1 rs9916765 1.9E-09  0 0 NA NA <1E-6 
GSDMB 15 11 5 rs2952140 1.2E-08  0 0 NA NA <1E-6 
ORMDL3 19 12 5 rs2952140 1.2E-08  2 0 rs4836703 0.4763 <1E-6 
MED24 5 5 2 rs7502514 4.8E-05  0 0 NA NA 1.1E-5 
NR1D1 5 4 2 rs12150298 2.8E-06  0 0 NA NA 4.4E-5 
TOP2A 1 1 1 rs2102928 4.1E-05  0 0 NA NA 4.6E-5 
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Table E4. Individual independent eQTLs contributing to a significant gene-based association test for 
TSLP. 
 
eQTL Study Tissue 
eQTL effect on gene 
expression  
eQTL effect on 
asthma risk 
 
Proxy-
eQTL 
phase 
Predicte
d effect 
of 
increase
d gene 
expressi
on on 
asthma 
risk 
A1 Beta P  Proxy tested A1 OR P 
rs12110124 11 LCLs C -3.3 6E-06  rs12110124 T 1.08 0.0022  Same Increase 
 
9
 Fibroblasts C -0.2 9E-09       Same Increase 
 
9
 Spleen C -0.8 2E-12       Same Increase 
rs17132582 7 Whole-blood A 4.0 5E-05  rs17132582 A 1.16 0.0003  Same Increase 
rs2289278 9 Fibroblasts G 0.3 5E-06  rs17132762 A 0.87 0.0028  AG/GC Increase 
rs252858 7 Whole-blood T -3.5 4E-04  rs252858 T 0.92 0.0167  Same Increase 
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Table E5. Linkage disequilibrium (r2) between the eQTLs most associated with asthma for each of 
the 11 genes in the 17q12 region that had a significant association with asthma. 
 Gene eQTL Asthma P-
value 
rs
12
15
02
98
 
rs
14
05
0 
rs
21
02
92
8 
rs
29
41
50
3 
rs
29
52
14
0 
rs
72
07
60
0 
rs
75
02
51
4 
rs
90
35
02
 
rs
99
16
76
5 
NR1D1 rs12150298 3.E-06 1.00         
GRB7 rs14050 1.E-07 0.84 1.00        
TOP2A rs2102928 4.E-05 0.01 0.01 1.00       
CISD3, 
STARD3 rs2941503 2.E-07 0.85 0.99 0.01 1.00      
GSDMB, 
ORMDL3 rs2952140 1.E-08 0.38 0.36 0.02 0.37 1.00     
IKZF3 rs7207600 4.E-07 0.08 0.08 0.18 0.09 0.21 1.00    
MED24 rs7502514 5.E-05 0.01 0.02 0.10 0.02 0.05 0.22 1.00   
PGAP3 rs903502 1.E-06 0.94 0.89 0.01 0.90 0.38 0.08 0.01 1.00  
ZPBP2 rs9916765 2.E-09 0.35 0.35 0.03 0.35 0.92 0.23 0.06 0.36 1.00 
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Table E6. Linkage disequilibrium (r2) between the eQTLs most associated with asthma for each of the 
13 genes in the MHC region that had a significant association with asthma.  
Gene eQTL Asthma P-value 
rs
10
63
35
5 
rs
13
21
50
91
 
rs
20
71
59
5 
rs
24
42
75
2 
rs
28
58
31
2 
rs
38
06
15
6 
rs
50
45
94
 
rs
52
22
54
 
rs
69
28
48
2 
rs
92
67
90
1 
rs
92
68
76
4 
rs
92
75
14
1 
rs
92
76
59
5 
HLA-DQB1 rs1063355 2.E-13 1.00             
HSPA1B rs13215091 5.E-04 0.00 1.00            
HCP5 rs2071595 7.E-06 0.02 0.40 1.00           
LTA rs2442752 2.E-05 0.00 0.01 0.02 1.00          
TAP2 rs2858312 2.E-05 0.18 0.00 0.18 0.01 1.00         
HLA-DRB1 rs3806156 1.E-04 0.15 0.02 0.03 0.01 0.07 1.00        
HLA-DQA1 rs504594 2.E-05 0.13 0.01 0.01 0.01 0.00 0.23 1.00       
HLA-DRB6 rs522254 6.E-04 0.05 0.01 0.01 0.00 0.00 0.26 0.58 1.00      
TAP1 rs6928482 2.E-08 0.67 0.00 0.01 0.01 0.33 0.30 0.20 0.10 1.00     
NEU1 rs9267901 9.E-04 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.02 0.03 1.00    
MICB rs9268764 3.E-05 0.23 0.01 0.03 0.00 0.19 0.22 0.24 0.19 0.33 0.00 1.00   
SLC44A4 rs9275141 1.E-06 0.54 0.00 0.01 0.02 0.41 0.31 0.17 0.08 0.86 0.03 0.27 1.00  
HLA-DQB1-AS1 rs9276595 4.E-02 0.03 0.00 0.02 0.00 0.18 0.02 0.01 0.02 0.10 0.00 0.01 0.13 
1.0
0 
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Table E7. Six genes associated with asthma at an empirical FDR of 0.05 that were not located in 
established risk loci for asthma but the significant gene-based associations were driven by trans-eQTLs 
located in the MHC region or near ORMDL3. 
 
Gene Chr N 
eQTLs 
cis-eQTLs  trans-eQTLs 
EUGENE 
P-value N 
Tested 
N with 
P<0.05 
Best individual eQTL  N 
Tested 
N with 
P<0.05 
Best individual eQTL 
SNP P-
value  SNP P-value 
LIMS1 2 15 4 0 rs1522021 0.4581  10 4 rs1063355 1.8E-13 <1E-6 
AOAH 7 26 17 0 rs2718180 0.0509  4 3 rs9268853 1.8E-06 1.5E-05 
ZNF707 8 9 7 2 rs11778657 0.0067  1 1 rs17609240 1.5E-06 4.5E-05 
TINF2 14 4 3 1 rs2273301 0.0010  1 1 rs3135006 1.7E-06 <1E-6 
CLK3 15 2 1 0 rs4646421 0.5147  1 1 rs9268853 1.8E-06 1.3E-05 
SAFB 19 2 1 0 rs2184854 0.6355  1 1 rs9268853 1.8E-06 1.0E-05 
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Table E8. Individual independent eQTLs contributing to a significant gene-based association test for 
LIMS1, AOAH, ZNF707, TINF2, CLK3 and SAFB. 
 
eQTLa Study Tissue 
eQTL effect on gene 
expression  
eQTL effect on 
asthma risk 
 
Proxy-
eQTL 
phase 
Predicted 
effect of 
increased 
gene 
expression 
on asthma 
risk 
A1 Beta P  Proxy tested A1 OR P 
LIMS1 
rs13192471 7 Whole-blood C -8.8 1E-18  rs13192471 T 1.08 0.0147  Same Increase 
rs443198 7 Whole-blood G 5.5 5E-08  rs443198 A 0.94 0.0076  Same Increase 
rs7765379 7 Whole-blood G 5.6 2E-08  rs7765379 T 0.92 0.0229  Same Increase 
rs9272346 7 Whole-blood G -14 4E-47  rs1063355 T 0.83 2E-13  TG/GA Increase 
AOAH 
rs674313 7 Whole-blood T 6.1 1E-09  rs617058 T 1.11 0.0035  TT/GC Increase 
rs9268853 17 Monocytes C -6.3 4E-09  rs9268853 T 0.89 2E-06  Same Decrease 
 
17
 
Monocytes-
LPS C -6.2 6E-09  rs9268853 T 0.89 2E-06  Same Decrease 
 
7
 Whole-blood C -14 1E-44  rs9268853 T 0.89 2E-06  Same Decrease 
 
12
 PBMCs T Pos. 1E-61  rs9268853 T 0.89 2E-06  Same Decrease 
rs9357155 7 Whole-blood A -4.6 4E-06  rs9357155 A 0.91 0.0047  Same Increase 
TINF2 
rs2273301 7 Whole-blood A 3.1 2E-03  rs2273301 A 0.85 0.0010  Same Decrease 
rs3135006 17 Monocytes T -8.1 5E-13  rs3135006 T 0.88 2E-06  Same Increase 
 
17
 
Monocytes-
LPS T -9.4 3E-16  rs3135006 T 0.88 2E-06  Same Increase 
ZNF707 
rs10097337 7 Whole-blood A 5.4 5E-08  rs10097337 A 0.95 0.0353  Same Decrease 
rs11778657 7 Whole-blood G 5.3 1E-07  rs11778657 A 0.93 0.0067  Same Increase 
rs17609240 7 Whole-blood T -4.6 4E-06  rs17609240 T 0.90 1E-06  Same Increase 
CLK3 
rs9268853 12 PBMCs T Pos. 7E-17  rs9268853 T 0.89 2E-06  Same Decrease 
SAFB 
rs9268853 7 Whole-blood C 4.7 3E-06  rs9268853 T 0.89 2E-06  Same Increase 
 
 
aIn bold: trans-eQTLs located in the MHC region. Underlined: cis-eQTLs. Italic: trans-eQTL located near ORMDL3. Pos.: 
positive beta. 
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Table E9. Association results in the Moffatt et al. 22 GWAS for the eleven genes that represent a 
potential novel genetic association with asthma. 
 
Gene Position N eQTLs tested 
N eQTLs with 
P<0.05 
Best individual eQTL EUGENE 
P-value SNP P-value 
B4GALT3 1:161141100 7 2 rs11587213 0.0102 0.0175 
P2RY14 3:150929905 9 1 rs2870518 0.0172 0.0412 
P2RY13 3:151044100 8 1 rs2870518 0.0172 0.0484 
P2RY12 3:151055168 6 0 rs3732765 0.0598 0.1165 
F12 5:176829141 3 0 rs2731672 0.4332 0.8810 
HIBADH 7:27565061 11 1 rs16874305 0.0442 0.4670 
REEP3 10:65281123 1 0 rs7915849 0.6660 0.6640 
USMG5 10:105148798 11 3 rs7897947 0.0004 0.0014 
PTCSC3 14:36605314 1 0 rs1766142 0.9076 0.9052 
DYNC1H1 14:102430865 3 0 rs12590618 0.6588 0.9530 
ACO2 22:41865129 2 0 rs132902 0.1161 0.1583 
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Table E10. Direction of effect on asthma risk for asthma-associated eQTLs in P2RY13, P2RY14, 
USMG5 and B4GALT3, in two independent GWAS. 
 eQTL  
eQTL effect in  
Ferreira et al 2014  
eQTL effect in  
Moffatt et al 2010  
LD between 
Ferreira and 
Moffatt proxies 
Consistency 
in direction 
of effect 
 Proxy tested A1 OR P  Proxy tested A1 OR P  r2 Phase 
P2RY13 
rs2870518  rs2870518 T 0.95 0.0364  rs2870518 T 0.95 0.0172  1.00 Same SNP Same 
rs6440732a  rs6440732 A 0.93 0.0102  rs1466684 G 1.02 0.4071  1.00 CG/AA Same 
rs6440742  rs6440742 T 0.94 0.0199  rs6781302 G 0.99 0.6044  0.95 GG/TA Opposite 
rs9814936  rs9814936 A 1.12 0.0001  rs9848789 T 0.96 0.1189  1.00 GT/AC Same 
rs9877416  rs9877416 A 0.90 0.0001  rs9877416 G 1.05 0.0770  1.00 Same SNP Same 
P2RY14 
rs10513393  rs10513393 A 0.89 0.0001  rs9848789 T 0.96 0.1189  1.00 AT/GC Same 
rs17204536  rs2276765 A 0.94 0.0125  rs3732765 G 0.96 0.0598  0.98 GA/AG Same 
rs2870518  rs2870518 T 0.95 0.0364  rs2870518 T 0.95 0.0172  1.00 Same SNP Same 
rs7616382  rs7616382 A 0.93 0.0271  rs1907637 G 0.98 0.3918  1.00 TA/AG Same 
rs9843590  rs9843590 A 1.08 0.0040  NA NA NA NA  NA NA NA 
USMG5 
rs11191724  rs11191724 A 0.95 0.0495  NA NA NA NA  NA NA NA 
rs1163073  rs1163073 T 0.92 0.0005  rs1163073 T 0.97 0.2240  1.00 Same SNP Same 
rs1572530  rs1572530 A 1.05 0.0644  rs7897947 T 0.91 0.0004  0.82 AG/GT Same 
rs17784294  rs17784294 A 0.95 0.0693  rs7904252 T 0.93 0.0020  0.97 AT/CG Same 
rs2250580  rs2250580 C 1.05 0.0734  rs2486757 T 1.06 0.0135  0.99 CT/GC Same 
rs2271750  rs2271750 A 0.91 0.0048  rs2271750 G 1.02 0.4629  1.00 Same SNP Same 
rs999867  rs999867 T 1.10 0.0211  rs999867 T 1.04 0.2720  1.00 Same SNP Same 
B4GALT3 
rs11579627  rs11579627 A 1.07 0.0124  rs11581556 G 1.04 0.1137  0.89 AA/GG Opposite 
rs11587213  rs11587213 A 1.04 0.1997  rs11587213 G 0.93 0.0102  1.00 Same SNP Same 
rs4233366  rs4233366 T 1.08 0.0033  rs4233366 T 1.05 0.0236  1.00 Same SNP Same 
rs1668873b  rs1668873 A 0.93 0.0015  rs7531256 T 1.02 0.3060  0.91 AG/GT Same 
ars6440732 is in LD (r2=0.94) with a missense SNP (rs1466684; T158M) in P2RY13. 
brs1668873 is a trans-eQTL; all others are cis-eQTLs. 
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Table E11. Direction of effect on gene expression and disease risk for asthma-associated eQTLs in 
P2RY13, P2RY14, USMG5 and B4GALT3. 
 
eQTLa Study Tissue 
eQTL effect on gene 
expression  
eQTL effect on 
asthma risk 
 
Proxy
-
eQTL 
phase 
Predicted 
effect of 
increased 
gene 
expression 
on asthma 
risk 
A1 Beta P  Proxy tested A1 OR P 
P2RY13 
rs2870518 7 Whole-blood C 4.7 2E-06  rs2870518 T 0.95 0.0364  Same Increase 
rs6440732 7 Whole-blood C 24 2E-125  rs6440732 A 0.93 0.0102  Same Increase 
rs6440742 7 Whole-blood G 10 2E-25  rs6440742 T 0.94 0.0199  Same Increase 
rs9814936 7 Whole-blood G -8.5 3E-17  rs9814936 A 1.12 0.0001  Same Increase 
rs9877416 7 Whole-blood G 5.6 2E-08  rs9877416 A 0.90 0.0001  Same Increase 
P2RY14 
rs10513393 6 Whole-blood NA NA 4E-56  rs10513393 A 0.89 0.0001  Same Increase 
 
7
 Whole-blood A -14 2E-42       Same Increase 
rs17204536 7 Whole-blood T 5.7 1E-08  rs2276765 A 0.94 0.0125  GT/AC Increase 
rs2870518 7 Whole-blood C 5 5E-07  rs2870518 T 0.95 0.0364  Same Increase 
rs7616382 7 Whole-blood T 3.4 8E-04  rs7616382 A 0.93 0.0271  Same Increase 
rs9843590 7 Whole-blood A 3.7 3E-04  rs9843590 A 1.08 0.0040  Same Increase 
USMG5 
rs11191724 7 Whole-blood A 8.8 1E-18  rs11191724 A 0.95 0.0495  Same Decrease 
rs1163073 18 Neutrophils C Pos. 5E-25  rs1163073 T 0.92 0.0005  Same Increase 
 
11
 LCLs C 73 4E-119       Same Increase 
 
15
 LCLs T -1.2 4E-116       Same Increase 
 
15
 Skin T -0.6 3E-90       Same Increase 
 
7
 Whole-blood C 64 1E-197       Same Increase 
 
12
 PBMCs C Pos. 0E+00       Same Increase 
rs1572530 12 PBMCs G Neg. 2E-15  rs1572530 A 1.05 0.0644  Same Increase 
rs17784294 11 LCLs A -19 2E-06  rs17784294 A 0.95 0.0693  Same Increase 
 
12
 PBMCs C Pos. 3E-14       Same Increase 
rs2250580 12 PBMCs C Pos. 2E-12  rs2250580 C 1.05 0.0734  Same Increase 
rs2271750 11 LCLs A -30 2E-06  rs2271750 A 0.91 0.0048  Same Increase 
 
7
 Whole-blood A -15 1E-48       Same Increase 
 
12
 PBMCs G Pos. 2E-13       Same Increase 
rs999867 15 LCLs T 0.6 3E-13  rs999867 T 1.10 0.0211  Same Increase 
 
15
 Skin T 0.3 1E-10       Same Increase 
 
12
 PBMCs T Pos. 5E-24       Same Increase 
B4GALT3 
rs11579627 13 Neutrophils A -0.1 3E-05  rs11579627 A 1.07 0.0124  Same Decrease 
rs11587213 9 Fibroblasts G Neg. 1E-07  rs11587213 A 1.04 0.1997  Same Increase 
 
7
 Whole-blood G -4.8 2E-06       Same Increase 
rs4233366 9 Fibroblasts T Pos. 2E-26  rs4233366 T 1.08 0.0033  Same Increase 
rs1668873 7 Whole-blood A 5 6E-07  rs1668873 A 0.93 0.0015  Same Decrease 
 
 
aIn bold: trans-eQTL. Pos.: positive beta. Neg.: negative beta. 
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Table E12. Primers used in gene expression analyses of RNA extracted from mouse lung. 
Gene Oligonucleotide Primer 
P2ry13 Forward: 5’- GTGGGTTGAGCTAGTAACTGCC-3’ Reverse: 5’- CATCCCAGTGGTGTTGATTG-3’ 
P2ry14 Forward: 5’- TCCTCCAGACACACTGATGC-3’ Reverse: 5’- AAAGGCAAGCTTCGTCAACA-3’ 
Hprt Forward: 5’- AGGCCAGACTTTGTTGGATTTGAA-3’ Reverse: 5’-CAACTTGCGCTCATCTTAGGCTTT-3’ 
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E FIGURE LEGENDS 
 
Figure E1. Number of independent eQTLs per gene identified from published GWAS of gene 
expression. 
 
Figure E2. Expression of P2ry13 and P2ry14 in lymphocytes (A), monocytes (B), conventional 
dendritic cells (C) and plasmocytoid dendritic cells (D) collected in BALF after saline or HDM 
challenge. 
Figure E3. In vivo exposure to P2ry13 and P2ry14 receptor agonists in naïve C57Bl/6 mice.  Total 
number of monocytes (A), neutrophils (B) and conventional dendritic cells (C) recruited to the BALF 
based on flow cytometry analysis. Veh: vehicle. HDM: house dust mite allergen. CRE: cockroach 
allergen. Alt: alternaria allergen.   
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